ProMIS Neurosciences Inc PMN

biogen suffering ?

[retiredcop]

Yes looks like the MS settlement hit  them pretty hard today.. a hate to see what happens when some good news comes out  

$270.8073.005 | 36.91%Bid: 270.60 x 200Ask: 270.89 x 100Volume: 11,787,065

USDNASDAQ GLOBAL SELECTDELAYED PRICESEPTEMBER 28, 2022 12:52 PMEDT

[retiredcop]

Sept 28 (Reuters) - Biogen Inc (BIIB.O) was set to add more than $10 billion to its market capitalization on Wednesday, as a surprise trial success of the experimental Alzheimer's drug it developed with Eisai (4523.T) was hailed as an unequivocal win by analysts.

[M101]

Exactly my point RC, cost of doing business.  I would call these guys corrupt except there is no such thing in the oligopoly.  It's like calling Crooks in Action corrupt, it's just a busines model.   

[DarylTheFrog]

I would say this Biogen news might gety our genertors turning again and get some eyes in here........We do need it..

[M101]

It's the sort of good but not too good news our consultants were hoping for when they hyped Aducanumab. I hope the new CEO leverages it more strategically this time, doesn't seem like it should be difficult.    .  

[G1945V]

What is there to leverage? Aducanumab is an expensive, lacklustre drug! G1945V

[M101]

I hope she leverages the modest benefit of lecanemab into a promotional strategy that stresses PMN310s differences rather than similarities. It's almost October, the baseball analogies practically write themselves. Lecanemab is a longer pop fly than Aducanumab, but they're both outs. Credit the player with making contact as opposed to all the earlier whiffs, but outs are still how you lose

[G1945V]

The difference with PMN310 has always been there. Targetting toxic oligomers. It can't be clearer than that. ProMIS has always made that very plain. Selectivity! The jury is still out for Lecanemab. Looks good though in keeping the amyloid-beta hypothesis alive. G1945V